ProteoNic’s 2G UNic™ technology drives significant value creation
Capture value, license ProteoNic technology
ProteoNic licenses to pharmaceutical and biotechnology companies as well as to CDMOs. Licenses are provided on a non-exclusive, world-wide basis.
ProteoNic offers two licensing models:
- product specific license
- platform license
Product licenses have upfront and milestone payments per product for a specified number of products. Platform licenses are provided for an unlimited number of products. Payment terms may vary from lump sum upfront buy-out payments to milestone-based payment schedules. Licensing terms are flexible and royalty-free.
Interested? Contact us
ProteoNic’s 2G UNic™ technology adds value in several domains:
1. Substantial improvements in productivity leads to significant economic impact on COGS savings
2. For difficult to express proteins, the added value goes beyond cost savings – as low levels of productivity may not be commercially viable
3. Increased productivity allows for expanded production capacity
Highly significant annual savings for total production costs and costs per gram of product.
Savings depend on production scale and are greatest at full commercial production.
Our flexible licensing options
We provide flexible, non-exclusive, royalty-free licenses and offer different payment options, ranging from lump sum buy-out to milestone-based payment schedules
Test 2G UNic™ in a proof-of-concept study, for a limited time period and number of products
We offer two options: using our technology in your vector, or integrating your gene into our fully optimized 2G UNic™ vector:
- ProteoNic designs expression vectors and supplies transfection-ready DNA
- ProteoNic provides fully optimized 2G UNic™ vectors with common selection cassettes
ProteoNic transfers the technology to you or your CDMO for transfection, stable pool generation, clone generation and analysis.
- No changes to your existing workflow
- Pool results predict performance of production cell lines
- Enables decision on commercial implementation
Commercial terms are pre-agreed, before execution of any evaluation study
- Platform or per-product
- Buy-out or milestone-based payment schedules
Upon execution of the commercial agreement, the technology and associated information is transferred to the licensee for full implementation to CLD activities and subsequent steps
If required, ProteoNic staff can remain available for consultation throughout the process
Selected commercial licensees
We provide access to our technology irrespective of company size or market segment. Our licensees include large pharma, biotech and CDMOs, as well as smaller players. Ultimately, our licensees provide validation of our technology and commercial model.
“ProteoNic’s validated expression platform technology improves cell line productivity, especially for complex bio-molecules, and supports the optimized GMP manufacturing of our NK engager multifunctional antibodies. We look forward to bringing our novel cancer therapeutics to clinical trials starting in 2021.”
Are you interested in offering 2G UNic™’s benefits to your customers?
2G UNic™ technology is broadly applicable in the entire therapeutic protein production industry.
Patented smart features make it suitable for different types of molecules across all commercially available mammalian expression systems.
Technical and commercial validation by third parties, including top-tier biopharma, demonstrates severalfold productivity increases, translating into cost savings of multimillion-euros per year.
Evaluation and commercial licensing agreements with pharma and biotech companies and distribution partnerships with CDMOs.
ProteoNic has a global client base consisting of large, mid-sized and small pharma and biotech companies and CDMOs.